ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,599.00
15.50 (0.98%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  15.50 0.98% 1,599.00 1,599.50 1,600.50 1,600.00 1,575.00 1,579.50 5,149,016 16:35:14
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.37 65.87B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,583.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £65.87 billion. Gsk has a price to earnings ratio (PE ratio) of 13.37.

Gsk Share Discussion Threads

Showing 32901 to 32924 of 33100 messages
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older
DateSubjectAuthorDiscuss
31/1/2024
14:39
Nothing's changed over the decades.It requires the US market to determine the reaction to figures.The UK flounders without a Wall Street lead.
steeplejack
31/1/2024
14:26
Good results that point to a growing and increasingly profitable future. Not wishing to count chickens before hatching but could it be that the much maligned CEO has done a good job and managed to redirect this oil tanker into more rewarding waters. I for one think so. She took on a helluva big job and we seem to be seeing the hard work beginning to pay off. There ain't nothin like a Dame.
pcok
31/1/2024
14:21
To be fair, things weren't too bad but then some woke up to Zantac and acted like GSK had put cyanide in all its marketed drugs :(
rikky72
31/1/2024
13:49
All good things….
patientcapital
31/1/2024
13:42
After years of waiting we are at last showing some form.
Things looking better after todays results.

careful
31/1/2024
13:20
This has done what DGE did yesterday!!

Good luck all 👍🏻

tuftymatt
31/1/2024
12:46
nice to buy at a low point and see it go up afterwards as the opposite can be regular happening..
lippy4
31/1/2024
12:18
Yes of course, whatever it's called. From memory wasn't this the acq for which they paid something like a 100% premium over the pre bid price when nearly all bids go for way less than that?

I don't want to get in too close to any share in my income port. I think that doing so can blind investors to the bigger picture of eps, cash flow, debt, yield etc. thinking that some wonder drug, in this case, will be a nice earner. How many times have such hopes been dashed?

So over the years as an income investor I've become just a numbers player on the fundamentals of a share. I wouldn't know camlipixant from my behind and if I chose to invest that way it would lead me astray, causing a love affair with the share and losing investment perspective. I know FA about the drug industry and don't want to know either.

So I take very little interest in the fine detail of any of my many holdings, just enough to know what industry they're in to ensure diversification. After that, it's the three main indicators: numbers, numbers, numbers.

anhar
31/1/2024
12:02
Anhar, do you mean Bellus Health Inc.?

That acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with refractory chronic cough. An excellent potential drug to boost the GSK portfolio of respiratory products.

tradermichael
31/1/2024
11:55
Quite a sudden turnaround is there some Zantac news?
mattboxy
31/1/2024
10:49
Bellend! Let's hope it doesn't end up justifying that name
rikky72
31/1/2024
10:45
Future looks good for sure! Think long term
mj19
31/1/2024
10:26
Welcome modest reduction in crushing debt burden. Small increase in divi anticipated for 2024 at 60p which is +3.4% on the 58p for 23. Forward yield at 1,520p is 3.9%.

Not too bad results looking at the whole picture but as a very long term holder and income investor, I don't really trust GSK that much. It has a patchy record.

Also, following the large acquisition of Bellend in the year, I see that they have forked out a further $1bn for yet another acq. after the year end. A partial sale of the HLN holding covers this cost though.

The general rule is that acqs are too often poor decisions and tend to destroy value. Not all but frequently.

anhar
31/1/2024
10:08
in for some more, as a long time holder i like the movement with the share price even if its small at least its progress in the right direction..
lippy4
31/1/2024
09:44
The reaction is not ridiculous

4th quarter eps 8.6p
Dividend 16p

spacecake
31/1/2024
09:21
The reaction is faintly ridiculous yet not unexpected by anyone who's been following for a while. Still need evidence of more pipeline progress plus Zantac filed in the completed drawer before this rerates.
rikky72
31/1/2024
09:17
Increased dividend of 16p declared for Q4 2023; 58p FY 2023; 60p expected for 2024
tradermichael
31/1/2024
08:36
GSK beats earnings expectations on blockbuster RSV jab
Ian Johnston in London

Strong vaccine sales powered British pharmaceutical company GSK to higher-than-expected earnings in 2023, as the company’s new RSV jab gained “blockbuster” status just over six months after its US launch.

Total sales rose 5 per cent year-on-year to £30.3bn, with adjusted operating profit of £8.8bn, ahead of analysts’ estimates. The company expects sales growth of 5 to 7 per cent in 2024, while it also raised its 2031 sales outlook to £38bn.

The business was helped by stronger than expected £1.2bn sales of Arexvy, its new vaccine for respiratory syncytial virus authorised in the US in May 2023, which has taken two-thirds of market share ahead of its only rival jab by Pfizer, while its shingles vaccine brought in £3.4bn.

tradermichael
31/1/2024
08:18
GSK, a pharmaceutical group, announced that 4Q adjusted EPS rose 25% on year to 28.9 pence and revenue was up 15% to 8.05 billion pounds, both at constant exchange rates. The company expects 2024 adjusted EPS growth of between 6% - 9%, compared with 16% in 2023.
mj19
31/1/2024
08:18
Really good results if i read them right, was expecting a lift in the share price .. well down we go, no surprise there - seems to happen so often with shares - good results and down they go.
simon8
31/1/2024
08:05
I'm in. 1525.60
panache1
31/1/2024
08:04
Going down nothing new
abdullla
31/1/2024
07:46
A start, but dividend increase needed to be nearer 5% to drive the share price on from here, especially with Zantac litigation still ongoing. They need to deal with this.
cumnor
31/1/2024
07:39
..."With this progress made, GSK has today announced upgraded outlooks, from those previously given, for the period 2021-2026 and for 2031. For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR basis and adjusted operating profit to increase more than 11%, on the same basis. This compares to previous outlooks of more than 5% and more than 10% respectively. Adjusted operating profit margin in 2026 is now expected to be more than 31%."Encouraging.
steeplejack
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older

Your Recent History

Delayed Upgrade Clock